NDAORALTABLET
Approved
Feb 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ALTACE (ramipril) by Pfizer is animals. First approved in 2007.
Drug data last refreshed 39m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALTACE (ramipril) is an oral angiotensin-converting enzyme (ACE) inhibitor approved for hypertension and post-myocardial infarction management. It works by inhibiting ACE, reducing angiotensin II formation and aldosterone secretion, leading to decreased vasopressor activity and blood pressure reduction. The drug is effective across racial populations, though Black patients show a smaller average response to monotherapy.
$0.002BPart D
LOE ApproachingProduct is approaching loss of exclusivity with modest Part D spending ($2M in 2023), signaling a contracting team and focus on cost-efficient operations rather than growth initiatives.
Mechanism of Action
animals. Angiotensin converting enzyme is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II,…
Indications
Worked on ALTACE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.